Dutasteride
- Generic Name
- Dutasteride
- Brand Names
- Avodart, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30F6N2O2
- CAS Number
- 164656-23-9
- Unique Ingredient Identifier
- O0J6XJN02I
- Background
Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediato...
- Indication
Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with tamsulosin.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Symptomatic benign prostatic hyperplasia (BPH)
- Associated Therapies
- -
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
- Conditions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00375765
- Locations
- 🇳🇱
GSK Investigational Site, Nijmegen, Netherlands
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 378
- Registration Number
- NCT00368979
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 302
- Registration Number
- NCT00363311
- Locations
- 🇨🇦
GSK Investigational Site, Trois Rivieres, Quebec, Canada
Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 80
- Registration Number
- NCT00309855
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
- Conditions
- Interventions
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2011-01-27
- Target Recruit Count
- 57
- Registration Number
- NCT00303446
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2007-04-18
- Lead Sponsor
- Urology of Virginia
- Target Recruit Count
- 60
- Registration Number
- NCT00274417
- Locations
- 🇺🇸
Urology of Virginia, Virginia Beach, Virginia, United States
TRADE-Testosterone Replacement and Dutasteride Effectiveness
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 53
- Registration Number
- NCT00194675
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-09-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 18
- Registration Number
- NCT00161421
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Dutasteride to Treat Women With Menstrually Related Mood Disorders
- Conditions
- Interventions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 34
- Registration Number
- NCT00082043
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels
- Conditions
- First Posted Date
- 2003-06-17
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00062790
- Locations
- 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.